Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于解散并清算产业投资合伙企业的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the dissolution and liquidation of an industrial investment partnership fund. It details the background, shareholder structure, and impact of the liquidation. The document is relatively short (1523 characters) and does not contain financial statements or detailed financial data. It is an announcement about a corporate action related to investment fund liquidation, not a financial report, earnings release, or management discussion. It does not fit into categories like Annual Report, Interim Report, or Capital Update. It is a regulatory announcement about a corporate event. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-28 Chinese
第八届董事局第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Shenzhen Haiwang Bioengineering Co., Ltd. It details the convening of the 25th meeting of the 8th Board of Directors, the approval of a resolution regarding the dissolution and liquidation of an investment partnership, and the voting results. There is no financial data, no mention of annual or quarterly reports, no audit information, and no shareholder voting results from a general meeting. The document is clearly about board decisions and resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Confidence is high due to clear keywords like "董事局会议决议公告" (Board of Directors meeting resolution announcement) and detailed voting results within the board meeting context.
2022-01-28 Chinese
2021年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2021 annual performance forecast (业绩预告) from Shenzhen Haier Bioengineering Co., Ltd. It provides estimated financial results for the full year 2021, including net profit and earnings per share, but explicitly states that the data is preliminary and unaudited, with final audited results to be disclosed in the annual report. The document is short (1121 characters) and serves as a performance forecast announcement rather than a full annual report. It does not contain full financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts. FY 2021
2022-01-27 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物工程股份有限公司2022年第一次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedural compliance of the 2022 first extraordinary general meeting (临时股东大会) of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting's convening, attendance, voting procedures, and results, and confirms that all were conducted in accordance with relevant laws and company regulations. The document does not contain financial statements or management discussion but serves as a legal certification of the meeting's validity and voting outcomes. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting results and legal validation of a shareholder meeting.
2022-01-21 Chinese
2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2022 First Extraordinary General Meeting" of Shenzhen Haier Bioengineering Co., Ltd. It details the meeting date, voting methods, attendance, and voting results on specific proposals. It includes legal opinions confirming the validity of the meeting and resolutions. There is no financial data, no detailed report content, and the document is relatively short (2415 characters). This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which reports official results from shareholder votes at a general meeting. It is not an Annual Report, Interim Report, or any other financial or management report. Therefore, the correct classification is DVA with high confidence.
2022-01-21 Chinese
监事会关于第八届监事会第十六次会议相关事项的意见
Board/Management Information Classification · 85% confidence The document is a statement from the supervisory board (监事会) of Shenzhen Haiwang Bioengineering Co., Ltd. regarding opinions on guarantees provided to subsidiaries and external guarantees. It discusses internal supervisory opinions on financial guarantees and risk control measures. The document is short (512 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, nor an earnings release or audit report. It is also not a regulatory filing or announcement of voting results. The content is related to board/management oversight and opinions on company guarantees, which aligns with Board/Management Information filings that cover announcements or opinions from company boards or supervisory bodies on management matters.
2022-01-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.